Literature DB >> 14510644

Selective lack of the C16:0 fatty acid isoform of sulfatide in pancreas of type II diabetic animal models.

Maria Blomqvist1, Thomas Osterbye, Jan-Eric Månsson, Thomas Horn, Karsten Buschard, Pam Fredman.   

Abstract

Sulfatide (3'-sulfogalactosyl-ceramide) is a glycosphingolipid mainly located in the nervous system, but has also been found in the islets of Langerhans. Previous studies have suggested that sulfatide is involved in insulin processing and secretion. In this study, sulfatide expression and metabolism in pancreas and isolated islets of the type II diabetes models, ob/ob- and db/db mouse, was investigated using TLC-ELISA, metabolic labelling and electron microscopy. As in non-diabetic Lewis rat and human pancreas, sulfatide was located in secretory granules of the beta cells. However, the type II diabetic animal models and their background strains had an altered sulfatide expression, involving the lack of the C16:0 sulfatide fatty acid isoform, compared to non-diabetic Lewis rat, BALB/c mouse and human pancreatic tissue, in which the two dominating pancreatic sulfatide isoforms C16:0 and C24:0 are expressed. Correspondingly, in isolated ob/ob islets, sulfatide synthesis excluded the production of C16:0 sulfatide. Insulin administration to ob/ob mouse, which lowers beta cell activity, resulted in significantly increased sulfatide expression in pancreas (p=0.0003), but still no expression of the C16:0 sulfatide isoform. In vitro, the C16:0 sulfatide was shown to be the isomer involved in the preservation of insulin crystals. Thus, it is hypothesized that the selection of sulfatide isomers in pancreas might be a genetic factor contributing to disease development in type II diabetic animal models.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 14510644     DOI: 10.1034/j.1600-0463.2003.1110905.x

Source DB:  PubMed          Journal:  APMIS        ISSN: 0903-4641            Impact factor:   3.205


  8 in total

Review 1.  Involvement of sulfatide in beta cells and type 1 and type 2 diabetes.

Authors:  K Buschard; M Blomqvist; T Osterbye; P Fredman
Journal:  Diabetologia       Date:  2005-09-06       Impact factor: 10.122

Review 2.  Role of sulfatide in normal and pathological cells and tissues.

Authors:  Tadanobu Takahashi; Takashi Suzuki
Journal:  J Lipid Res       Date:  2012-05-22       Impact factor: 5.922

3.  Synthetic sulfogalactosylceramide (sulfatide) and its use for the mass spectrometric quantitative urinary determination in metachromatic leukodystrophies.

Authors:  Yanli Cui; Benoit Colsch; Carlos Afonso; Carlos Alonso; Nicole Baumann; Jean-Claude Tabet; Jean-Maurice Mallet; Yongmin Zhang
Journal:  Glycoconj J       Date:  2007-08-15       Impact factor: 2.916

Review 4.  Sphingolipids in obesity, type 2 diabetes, and metabolic disease.

Authors:  S B Russo; J S Ross; L A Cowart
Journal:  Handb Exp Pharmacol       Date:  2013

5.  NKT cells stimulated by long fatty acyl chain sulfatides significantly reduce the incidence of type 1 diabetes in nonobese diabetic mice [corrected].

Authors:  Lakshmimathy Subramanian; Hartley Blumenfeld; Robert Tohn; Dalam Ly; Carlos Aguilera; Igor Maricic; Jan-Eric Mansson; Karsten Buschard; Vipin Kumar; Terry L Delovitch
Journal:  PLoS One       Date:  2012-05-23       Impact factor: 3.240

6.  Uptake of the glycosphingolipid sulfatide in the gastrointestinal tract and pancreas in vivo and in isolated islets of Langerhans.

Authors:  Maria Blomqvist; Thomas Osterbye; Jan-Eric Månsson; Karsten Buschard; Pam Fredman
Journal:  Lipids Health Dis       Date:  2006-10-17       Impact factor: 3.876

Review 7.  Roles of ceramide and sphingolipids in pancreatic β-cell function and dysfunction.

Authors:  Ebru Boslem; Peter J Meikle; Trevor J Biden
Journal:  Islets       Date:  2012 May-Jun       Impact factor: 2.694

8.  Sulfatide Inhibits HMGB1 Secretion by Hindering Toll-Like Receptor 4 Localization Within Lipid Rafts.

Authors:  Hee Sue Kim; Myeonggil Han; In Ho Park; Cheol Ho Park; Man Sup Kwak; Jeon-Soo Shin
Journal:  Front Immunol       Date:  2020-06-23       Impact factor: 7.561

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.